There is much evidence that clotting factor concentrates (CFC), especially the so-called intermediate-purity preparations, exert an immunomodulating effect in vitro. The impact of this effect on the outcome of human immunodeficiency virus (HN) infection in hemophiliacs is still controversial. In this retrospective cohort study, the effects of treatment with CFC on mortality and progression to acquired immunodeficiency syndrome (AIDS) were estimated while controlling for individual risk factors. Logistic regredon and survival analysis, including the Cox proportional-hazards regression model, were performed with data from a 1 l-year follow-up of 225 hemophilic patients seropositive for HIV type 1 (HIV-1) of two hemophilia centers. Mortalii and progression to AIDS rates were strongly associated with lower administra-
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I
T IS WELL ESTABLISHED that clotting factor concentrates (CFC), especially factor VI11 concentrates, widely used in recent years in the management of hemophilia interact with immune function. This fact is supported by in vitro data. Factor VI11 concentrates inhibit in vitro lymphocyte proliferation and interleukin-2 production by T lymphocytes'.' and downregulate monocyte fun~tion.~ These observations have not been found with modem CFC, which are largely more purified from plasma source than are classic intermediate-purity concentrates (100 to 3,000 IU/mg of plasma protein v 0.5 to 25 IU/mg). Therefore, it is suggested that plasma proteins contaminating the intermediate-purity concentrates, which are not present in the modem high-purity preparations, are factors interacting with immune functions. The nature of substances interfering with immune system has not been established, although it is clear that they are not major contaminating proteins (eg, fibrinogen, fibronectin, Igs, and alb~rnin).~ Although not well established, it has been postulated that CFC act by increasing virus shedding by human immunodeficiency virus (H1V)-infected T lymphocytes after alloantigen stimulation by CFC contaminants and by an inhibitory effect on normal T-helper lymphocytes.4. ' The immunomodulating effect of CFC has caused great concern with regard to progression of HIV infection in hemophiliacs. Although different studies following a variety of designs have been focused on this subject,"' the impact of CFC on the outcome of HIV infection in hemophiliacs is still controversial." In this study, a well-characterized cohort of HJY-infected hemophilic patients from two centers of hemophilia were followed-up retrospectively from 1983 to 1993. The goal of this study was to estimate the effects of CFC use on the incidence of acquired immunodeficiency syndrome (AIDS)-defining events and mortality, after controlling for individual age, severity of clotting factor deficiency, and other potential risk factors.
MATERIALS AND METHODS

Study population.
All HIV-l-infected patients routinely controlled at the beginning of 1983 in two hemophilia centres (Unidad tion of CFC. After adjusting for age, a statistically signifcant and robust association was observed. The use of CH: was negatively associated with progression to AIDS ( P = .0252) and mortalii (P = .0033). The adjusted relative hazards of mortality and progression to AIDS rate between the most treated patients (>700 IU/kg/yr) versus the least treated (5700 IU/kg/yr) were 0.53 (confidence limits, 0.33 to 0.86) and 0.57 (0.39 to 0.84). respectively. Although the effects of other unmeasured risk factors cannot be excluded with certainty, these results suggest that there is a negative association between treatment with CFC and progression to AIDS and mortality. 0 1995 by The American Society of Hematology.
de Hemofilia, Hospital Vall d'Hebron [Barcelona] and Centro de Coagulopatias, Hospital la Fe [Valencia]) were selected. Of the 259 patients initially followed-up, 4 were excluded because they belonged to another risk population (3 drug abusers and l homosexual) and 7 were excluded because of death not related to HIV (6 for central nervous system [CNSI-related bleeding and 1 gastrointestinal-related bleeding). Of the remaining 248 patients, 23 were lost for control in the follow-up. Finally, 225 patients were included in the cohort. Demographic characteristics of the selected patients included in the cohort are summarized in Table 1 .
All patients had received treatment with CFC before 1983, so in the absence of other risk factors, it is assumed that seroconversion to HIV infection was directly related to these concentrates. The year taken for seroconversion to HIV was 1982 because 1982 is considered to have the highest hazard of HIV infection in hemophiliacs, according to recent epidemiologic studies."." Seropositivity to HIV was determined by enzyme-linked immunosorbent assay (ELISA) since 1985 and was more recently confirmed for all patients with Western blot testing.
Factor concentrates. Data related to CFC use had been recovered for each patient from archives of the two hemophilia centers involved. More accurately, for the Barcelona cohort data were obtained from pharmacy records because the Pharmacy Service keeps accurate records of CFC delivery to hemophilic patients. In Spain, the treatment with CFC is covered by the Public Health System and its delivery is centralized in the Pharmacy Services of Public Hospitals. For the Valencia cohort, data were obtained from patient treatment diaries and clinical records. The amount of CFC used yearly was divided by annual mean body weight to express CFC as international units per kilogram per year. Finally, the arithmetical Includes von Willebrand's disease, factor l1 deficiency, and factor X deficiency.
<l% standard activity in healthy subjects), moderate (1% to 5%). and mild (>5%). Clinical events. Causes of death were obtained from clinical records and death certificates (85%), autopsy reports (4%). and official declarations of AIDS-related death to Health Autorities (1 1 S). Any death occumng during the follow-up period was defined as HIV related unless it was conclusively known not to be HIV related.
Progression The distribution of all quantitative variables was examined to detect significant departures from normality by means of a Shapiro-Wilks test. When present, a newly derived variable with better performance was computed. However, for descriptive purposes, the mean ? SD was used independently of the distribution.
Intergroup comparisons involving quantitative variables were performed using two-tailed t-tests for independent samples. Confusion and interaction effects of age were evaluated by multiple logistic regression analysis. The criteria used to enter or remove a variable from the model were a probability of the x ' approximation for the likelihood ratio of 0.05 and of 0.1, respectively, and a convergence criteria of estimate parameters and logarithm of the likelihood ratio of 0.0001.
The survival curve estimation and the proportion of patients free from AIDS were assessed by means of the Kaplan-Meier productlimit estimator. The median time from entry and cumulative proportion of patients free from event were computed. Pairs of survival curves were compared using the log-rank test. Factors affecting outcome were assessed with the Cox proportional-hazards regression model. Statistical tests of the regression coefficients were based on the x* approximation for the likelihood-ratio statistic. The criteria used to enter or remove a variable were a probability of 0.05 and of 0.1, respectively. The combined effects of the risk factors were explored using a statistical test for interaction. Time was measured by years, given that the follow-up period includes more than 10 divisions of this unit.
All reported P values are two-sided. A P value less than .05 was considered to indicate statistical significance.
RESULTS
Study population. The characteristics of each cohort and of the whole group are shown in Table 1 . The two cohorts were homogeneous in severity of the clotting factor deficiency, mean CFC use, and final status. Little difference was present with respect to hemophilia type and age. The whole group was relatively young (median, 16 years; 25th to 75th percentiles range, 8 to 25 years). There was a predominance of hemophilia A (88%) and of patients with severe (<l% of the standard activity) deficit of clotting factor (74%). Median CFC use was 684 IU/kg/yr (25th to 75th percentiles range, 280 to 1,416 IU/kg/yr).
The Shapiro-Wilks test showed a least departure from normality for a square root of both age and CFC use. Therefore, all statistical tests were performed with the respective square root.
The final status was AIDS-related death in 72 (32%) patients, AIDS in 49 (22%), lymphocyte CD4' cell counts less than 400 cells/mL in 77 (34%), and CD4' cell counts equal or more than 400 celldmL in 27 (12%).
Progression to AIDS and mortality. Table 2 shows the clinical characteristics of patients that developed AIDS and of patients who died of AIDS compared with those that did not. No association was found between coagulation disorder or seventy of the clotting factor deficiency and either AIDS or death; however, a strongly statistically significant association was found between progression to AIDS or death and age, mean CFC use, and previous CFC use. The mean age was 21 2 14 years in patients who developed A I D S and 15 t 9 years in those that did not (P = .001). The mean age was 24 -C 15 years in patients who died and 15 ? 10 years in those who are alive at the end of the study (P .OOO5). CFC use higher than 700 UIflrglyr was 0.6 (confidence limits, 0.4 to 0.8) to develop AIDS and 0.2 (0.1 to 0.6) to die.
The association between the mean CFC use and death (Fig 1) or AIDS (Fig 2) was not statistically significant in several strata when subgroup analysis was performed according to coagulation disorder, severity of clotting factor deficiency, and previous CFC use. Nevertheless, these Variables were not considered to be confounders or modifiers but to be intermediates and were therefore not included in the logistic regression model. When stratified by age, both significance and intensity of the association between mean CFC use and AIDS or death strongly changed. Furthermore, these two variables are inversely correlated (Pearson r = -.306, P < .OOOS). Therefore, in subsequent analysis, the effect of age on mean CFC use was controlled.
Multiple logistic regression retained both the squared root of the mean CFC use and the squared root of the age as independent predictors of death (global X', 34.30; P < .oooO5) and progression to AIDS (global X', 15.81; P = . OOO4) without interaction between these two risk factors. These logistic functions explain the 72.9% and 64.4% of the variability found, respectively. to AIDS. By 5 and 10 years after seroconversion, death had occurred in 8.44% (confidence limits, 5% to 12%) and 25% (19% to 31%), respectively, and the cumulative incidence of AIDS was 11% (7% to 15%) and 40% (32% to 46%), respectively.
Negative association between the mean CFC use on the time to die or develop AIDS and positive association with age remain present, according to the Cox regression model (global x*, 32.78; P < .00005 for death; and global X', 11 .81 ; P = .W06 for progression to AIDS). No significant interaction was found between age and mean CFC use. Relative hazards on death were 0.97 (95% confidence limits, 0.96 to 0.99) for the square root of the mean CFC use and 1.39 (1.17 to 1.65) for the square root of the age. Relative hazards on progression to AIDS were 0.99 (0.97 to 1.00) and 1 .l8 ( l .03 to 1.34), respectively.
The log-rank test, after adjustment for age, showed that the relative hazards in the patients with CFC use less than 700 IU/kg/yr is 0.53 (confidence interval, 0.33 to 0.86; Fig  3) on death and 0.57 (0.39 to 0.84; Fig 4) on progression to AIDS.
DISCUSSION
In recent years, attention has been focused on the interaction between administered CFC and the immune system of hemophiliacs seropositive to HIV-1." At this moment, most of HIV-infected hemophiliacs have been switched to treatment with high-purity CFC. This fact makes it difficult to undertake a long-term prospective follow-up on the influence of classic intermediate-purity CFC on the occurrence of AIDS-defining diagnoses and mortality of HIV-infected hemophiliacs.
In this cohort study, mortality and progression to AIDS, adjusted for known risk factors, are strongly associated with administered CFC, but, strikingly, higher amounts of CFC usage are associated with a slowing down in the progression of HIV-1 infection to AIDS and AIDS-related mortality. As with all other epidemiologic studies, it is possible that the observed association is due to confounding resulting from a risk factor that is correlated with both CFC exposure and progression to AIDS or mortality. Potential confounders of effects of CFC use not controlled in the study are unknown at this moment. Nevertheless, it is important to state that the results are consistent in both cohorts (Barcelona and Valencia). Although the Valencia cohort was not statistically significant, the magnitude of the effect is comparable. The lack of significance in this case is probably related to the relatively low number of patients of the Valencia cohort.
Assuming that CFC exerts a protective effect on HIV-1-infected hemophiliacs, one would expect a longer survival time in series involving hemophiliacs. In this cohort, there is a mortality of 32% and a cumulative incidence of AIDS of 54% after 11 years of follow-up. Studies in hemophiliacs with similar follow-up periods are coincident and show mortality of 3 1 % (1 2 years) and 41 % (1 1 years) and cumulative incidence of AIDS of 6 6 % and 42% (not 1993 CDC criteria), respectively.l5.l6 Unfortunately, differences, if present, with other risk populations (transfusion recipients, homosexuals, and injection-drug users) cannot be evaluated from a statistic point of view. Nevertheless, the incidence of AIDS-related malignancies, such as Kaposi sarcoma, are rare among hemophilic patients. Because this tends to occur in patients with higher CD4+ cell counts than in patients with other AIDS-defining conditions, it might be expected that people with hemophilia would progress more slowly than would other risk groups.I6
In light of the results it seems evident that there is no association between coagulation disorder or seventy of hemophilia with progression of HIV infection. These results are coincident with those from a previous study.I7 The strong association between age and progression to A m S or mortality is not surprising given that it has been widely described not only for hemophiliacs but also for other risk groups.'* Patients with lower previous CFC use have a significantly increased risk of progression to AIDS or death. Initially, it was suggested that patients with smaller infecting inoculum would probably have a slower progre~sion.'~,'~ This consideration might be true, but in our case the strong association between previous CFC and CFC use after starting the followup probably completely obscures such a supposition. The strength of the observed association between CFC use and AIDS-related mortality and progression to AIDS has not been observed in previous studies. In most cases, CFC use was not considered as a potential cofactor.I6 The cumulative dose of plasma concentrate was not demonstrably related to the incidence of AIDS even if stratified by age, as expressed by investigators in a previous study.17 However, it must be stated that the crude cumulative dose of plasma concentrate may not be the most accurate expression of CFC use, as shown in an early evaluation of the Valencia cohort." It is more realistic to normalize CFC use by weight and year, excluding its use after progression to AIDS, thus avoiding the influence of AIDS condition on CFC use. Nevertheless, 1884 1 986 1988 1990 1992 Year the latest studies show increasing coincidences with our results, ie, a faster progression towards AIDS in hemophiliacs using lower yearly amounts of factor VI11 concentrates (520,000 IU) than those using higher amounts;' and that 78% of the current asymptomatic patients were severe hemophiliacs, receiving more than 20,000 Wyr.2' This study provides precise estimates of the protective effect of CFC on the progression of HIV infection in hemophiliacs. The relative hazard, adjusted for age, of AIDSrelated death in patients with higher CFC use (>700 IU/ kg/yr) is 0.53 (95% confidence interval, 0.33 to 0.86). For progression to AIDS, the relative hazard is 0.57 (0.39 to 0.84). After 11 years of follow-up, death resulted in 20% patients with a CFC use greater than the median (700 IU/ kg/yr) and in 43% patients of the lowest half of CFC use. Progression to AIDS resulted in 43% and 65% patients, respectively.
Assuming that our results are not a consequence of another unmeasured risk factods), an easy explanation for primary protective mechanism cannot be given. Nonetheless, a hypothesis can be advanced. It is widely recognized that CFC, especially classic intermediate-purity products, interact with the immune system. The nature of this interaction is not well Year established, but the ultimate consequence could be a delayed progression of HIV infection. Recently, increasing importance has been given to the presence of immunomodulating proteins in intravenous Igs, another group of plasma-derived dr~gs.".~ Similarly, CFC (with the exception of very high punty preparations) contain appreciable amounts of transforming growth factor-p (TGF-p). 25 Finally, it is quite important to more deeply evaluate (in other series) the association between CFC use and the progression of HIV infection in hemophilic patients to assess accurately, if confirmed, the power of the effect and to identify and isolate the responsible substances. For personal use only. on October 22, 2017. by guest www.bloodjournal.org From
